Martinez-Hervas Sergio, Carmena Rafael, Ascaso Juan F, Real Jose T, Masana Luis, Catalá Miguel, Vendrell Joan, Vázquez José Antonio, Valdés Sergio, Urrutia Inés, Soriguer Federico, Serrano-Rios Manuel, Rojo-Martínez Gemma, Pascual-Manich Gemma, Ortega Emilio, Mora-Peces Inmaculada, Menéndez Edelmiro, Martínez-Larrad Maria T, López-Alba Alfonso, Gomis Ramón, Goday Albert, Girbés Juan, Gaztambide Sonia, Franch Josep, Delgado Elías, Castell Conxa, Castaño Luis, Casamitjana Roser, Calle-Pascual Alfonso, Bordiú Elena
Service of Encodrinology and Nutrition, Hospital Cliníco Universitario de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria HCUV-INCLIVA, Spain; Department of Medicine, University of Valencia, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain.
Service of Encodrinology and Nutrition, Hospital Cliníco Universitario de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria HCUV-INCLIVA, Spain; Department of Medicine, University of Valencia, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain.
Clin Investig Arterioscler. 2014 May-Jun;26(3):107-14. doi: 10.1016/j.arteri.2013.12.001. Epub 2014 Jan 23.
Dyslipidemia is a significant contributor to the elevated CVD risk observed in type 2 diabetes mellitus. We assessed the prevalence of dyslipidemia and its association with glucose metabolism status in a representative sample of the adult population in Spain and the percentage of subjects at guideline-recommended LDL-C goals.
The di@bet.es study is a national, cross-sectional population-based survey of 5728 adults.
A total of 4776 subjects were studied. Dyslipidemia was diagnosed in 56.8% of subjects; only 13.2% of subjects were treated with lipid lowering drugs. Lipid abnormalities were found in 56.8% of Spanish adults: 23.3% with high LDL-C, 21.5% high TG, 35.8% high non-HDL-C, and 17.2% low HDL-C. Most normal subjects showed an LDL-C ≤ 3.36 mmol/l. Pre-diabetics presented similar proportion when considering a goal of 3.36 mmol/l, but only 35% of them reached an LDL-C goal ≤ 2.6 mmol/l. Finally, 45.3% of diabetics had an LDL-C ≤ 2.6 mmol/l, and only 11.3% achieved an LDL-C ≤ 1.8 mmol/l.
Our study demonstrates a high prevalence of dyslipidemia in the adult Spanish population, and a low use of lipid-lowering drugs. Moreover, the number of subjects achieving their corresponding LDL-C goal is small, particularly in subjects at high cardiovascular risk, such as diabetics.
血脂异常是2型糖尿病患者心血管疾病风险升高的重要因素。我们评估了西班牙成年人群代表性样本中血脂异常的患病率及其与糖代谢状态的关联,以及达到指南推荐的低密度脂蛋白胆固醇(LDL-C)目标的受试者百分比。
di@bet.es研究是一项针对5728名成年人的全国性横断面人群调查。
共研究了4776名受试者。56.8%的受试者被诊断为血脂异常;仅13.2%的受试者接受了降脂药物治疗。在56.8%的西班牙成年人中发现了血脂异常:23.3%的人低密度脂蛋白胆固醇升高,21.5%的人甘油三酯升高,35.8%的人非高密度脂蛋白胆固醇升高,17.2%的人高密度脂蛋白胆固醇降低。大多数正常受试者的低密度脂蛋白胆固醇≤3.36 mmol/l。考虑到目标值为3.36 mmol/l时,糖尿病前期患者的比例相似,但其中只有35%的人达到了低密度脂蛋白胆固醇目标值≤2.6 mmol/l。最后,45.3%的糖尿病患者低密度脂蛋白胆固醇≤2.6 mmol/l,只有11.3%的人达到了低密度脂蛋白胆固醇≤1.8 mmol/l。
我们的研究表明,西班牙成年人群中血脂异常的患病率很高,而降脂药物的使用较少。此外,达到相应低密度脂蛋白胆固醇目标的受试者数量很少,尤其是在心血管疾病高风险人群中,如糖尿病患者。